FIELD: biotechnology.
SUBSTANCE: disclosed are methods of treating acute myeloid leukaemia (AML) in a subject. Immunoconjugate binding to CD123 in combination with venetoclax and/or azacytidine is administered to the specified subject. Immunoconjugate contains an antibody or its antigen-binding fragment linked to a DNA-alkylating agent. Antibody or antigen-binding fragment contains the heavy chain variable region CDR1, CDR2 and CDR3 containing SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7; and CDR1, CDR2 and CDR3 of the light chain variable region, containing SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
EFFECT: inventions provide effective treatment of AML, and significant inhibition of tumour growth, and prolonged survival.
32 cl, 11 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
| THERAPEUTIC COMBINATIONS CONTAINING ANTI-FOLR1 IMMUNOCONJUGATES | 2016 |
|
RU2749865C2 |
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| ANTI-FOLR1 IMMUNOCONJUGATE APPLICATION SCHEMES | 2014 |
|
RU2801307C1 |
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| METHODS OF USING IMMUNOCONJUGATES CONTAINING ANTI-CD79B ANTIBODY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | 2020 |
|
RU2827797C1 |
| ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF | 2016 |
|
RU2739612C2 |
| COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
| HDM2-P53 INHIBITOR AND BCL2 INHIBITOR INTERACTION COMBINATIONS AND THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2793123C2 |
